Drug Profile
ZRC 3278
Alternative Names: AZD13721412; MMV253; MMV674253; ZRC-3278Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator AstraZeneca; Medicines for Malaria Venture
- Developer Zydus Cadila
- Class Antimalarials; Small molecules
- Mechanism of Action Vacuolar proton-translocating ATPase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Malaria in India
- 08 Jan 2019 Zydus Cadila plans a first-in-man clinical trial for Malaria in 2019 (Medicines for Malaria Venture pipeline, January 2019)
- 22 Jun 2017 Preclinical trials in Malaria in India before June 2017 (Zydus Cadila pipeline, June 2017)